Bragar Eagel & Squire, P.C. Is Investigating Allianz, TrueBlue, and GoodRx and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Allianz SE (OTC:ALIZY ) TrueBlue, Inc. (NYSE:TBI ), and GoodRx Holdings, Inc. (NASDAQ:GDRX ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. Allianz SE (OTC:ALIZY ) On August 1, 2021, Allianz disclosed that "the U.S. Department of Justice (‘DOJ') has begun an investigation concerning the Structured Alpha Funds," and that "there is a relevant risk that the matters relating to the Structured Alpha Funds could materially impact future financial results of Allianz Group." On this news, Allianz's stock price fell $2.00 per share, or 8%, to close at $22.85 per share on August 2, 2021. Then, on May 17, 2022, Allianz pleaded guilty to securities fraud, admitting that it lacked internal controls and oversight for a series of private-investment funds and made false and ... Full story available on Benzinga.com